HER2-positive

About

Biomarker Type: Protein expression

Present: True

Marker: Human epidermal growth factor receptor 2 (HER2)

Unit: status

Equality: =

Value: Positive


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Paclitaxel, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Margetuximab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Eribulin, Margetuximab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Gemcitabine, Margetuximab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Margetuximab, Vinorelbine FDA
Sensitivity (+) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Capecitabine FDA
Sensitivity (+) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Neratinib HC
Sensitivity (+) ER positive, HER2-positive Invasive Breast Carcinoma Neratinib HC
Sensitivity (+) HER2-positive, PR positive Invasive Breast Carcinoma Neratinib HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Neratinib HC
Sensitivity (+) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab FDA
Sensitivity (+) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab, Vinorelbine HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab emtansine HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab emtansine HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Trastuzumab, Tucatinib HC
Sensitivity (+) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab deruxtecan HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab deruxtecan HC
Sensitivity (+) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Trastuzumab deruxtecan HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib FDA
Sensitivity (+) ER positive, HER2-positive Invasive Breast Carcinoma Lapatinib, Letrozole FDA
Sensitivity (+) HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole FDA
Sensitivity (+) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Paclitaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab, Vinorelbine HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab HC
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Neratinib FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Neratinib FDA
Sensitivity (+) HER2-positive Intraductal Papillary Neoplasm of the Bile Duct Zanidatamab FDA
Sensitivity (+) HER2-positive Intracholecystic Papillary Neoplasm Zanidatamab FDA
Sensitivity (+) HER2-positive Cholangiocarcinoma Zanidatamab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab emtansine FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab emtansine FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab FDA
Sensitivity (+) HER2-positive Gastrointestinal Stromal Tumor Trastuzumab FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Trastuzumab deruxtecan FDA
Sensitivity (+) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Trastuzumab deruxtecan FDA
Sensitivity (+) HER2-positive Any solid tumor Trastuzumab deruxtecan FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab deruxtecan FDA
Sensitivity (+) HER2-positive Invasive Breast Carcinoma Capecitabine, Trastuzumab, Tucatinib FDA
Sensitivity (+) HER2-positive, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Trastuzumab, Tucatinib FDA